The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats

doi:10.19439/j.sjos.2022.06.011

Abstract

Abstract: PURPOSE: To study the expression level of semaphorin 4D (Sema4D) in bisphosphonate-related osteonecrosis of the jaw (BRONJ) and to explore its possible role in the occurrence of BRONJ. METHODS: BRONJ-like rat model was established by intraperitoneal injection of zoledronic acid assisted with tooth extraction. The maxillary specimens were extracted for imaging and histological examination, and bone marrow mononuclear cells(BMMs) and bone marrow mesenchymal stem cells(BMSCs) of each group were obtained in vitro for co-culture. Trap staining and counting were performed on monocytes after osteoclast induction. RAW264.7 cells were induced by osteoclast orientation under bisphosphonates(BPs) environment, and Sema4D expression was detected. Similarly, MC3T3-E1 cells and BMSCs were induced to osteogenic orientation in vitro, and the expression level of osteogenic and osteoclastic related genes ALP, Runx2, and RANKL was detected under the intervention of BPs, Sema4D and Sema4D antibody. Statistical analysis of the data was performed using GraphPad Prism 8.0 software. RESULTS: BRONJ-like rat model was successfully constructed. Two weeks after tooth extraction, the healing of the tooth extraction wound in the experimental group was significantly limited, and the tooth extraction wound was exposed. H-E staining results showed that regeneration of new bone in the extraction socket of the experimental group was significantly restricted, dead bone was formed, and the healing of the soft tissue was limited. The results of trap staining showed that the number of osteoclasts in the experimental group was significantly less than that in the control group. Micro-CT results showed that bone mineral density and bone volume fraction in the extraction socket of the experimental group were significantly lower than those of the control group. Immunohistochemical results showed that compared with the control group, the expression level of Sema4D in the experimental group was significantly increased. In vitro studies showed that compared with the control group, the osteoclast induction of BMMs in the experimental group was significantly lower than that in the control group. BMSCs in the experimental group significantly reduced the induction of osteoclasts. Osteoclastic induction experiments revealed that bisphosphonates could effectively inhibit the formation of osteoclasts, and the expression of Sema4D was significantly reduced. Osteogenic induction experiment found that Sema4D significantly reduced the expression of Runx2 and RANKL genes in osteoblasts, while the expression of ALP gene decreased and the expression of RANKL up-regulated after adding Sema4D antibody. CONCLUSIONS: BPs can interfere with normal bone healing time by up-regulating the expression of Sema4D in tissues, leading to coupling disorder between osteoclasts and osteoblasts with inhibition of the maturation of osteoclasts, thereby inhibiting the growth of osteoblasts. Differentiation and expression of related osteogenic factors mediate the development of BRONJ.

Key words: Bisphosphonate-associated osteonecrosis of the jaw, Bisphosphonates, Semaphorin 4D, Bone marrow monocytes, Osteoclasts, Osteoblasts

CLC Number:

R782.3

PAN Qiao-ting, ZANG Xiao-long, SUN Zhao-wei, PAN Meng-qi, ZHU Xin-mei, LI Zhi-yong. The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats[J]. Shanghai Journal of Stomatology, 2022, 31(6): 625-631.

References

[1] Mcclung MR, Bolognese MA, Brown JP, et al.A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab[J]. Osteoporos Int, 2020, 31(11): 2231-2241.
[2] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9): 1115-1117.
[3] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10): 1938-1956.
[4] Chen X, Wang Z, Duan N, et al.Osteoblast-osteoclast interactions[J]. Connect Tissue Res, 2018, 59(2): 99-107.
[5] Eriksen EF.Cellular mechanisms of bone remodeling[J]. Rev Endocr Metab Disord, 2010, 11(4): 219-227.
[6] Koerdt S, Dax S, Grimaldi H, et al.Histomorphologic characteristics of bisphosphonate-related osteonecrosis of the jaw[J]. J Oral Pathol Med, 2014, 43(6): 448-453.
[7] Bayram H, Kenar H, Taşar F, et al.Effect of low level laser therapy and zoledronate on the viability and ALP activity of Saos-2 cells[J]. Int J Oral Maxillofac Surg, 2013, 42(1): 140-146.
[8] Huang X, Huang S, Guo F, et al.Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro[J]. Mol Med Rep, 2016, 13(1): 613-622.
[9] Demircan S, Isler SC.Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: a case control study[J]. Niger J Clin Pract, 2020, 23(2): 154-158.
[10] Nagaoka Y, Kajiya H, Ozeki S, et al.Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition[J]. J Dent Res, 2015, 94(4): 594-601.
[11] Wang L, Li X, Song Y, et al.The emerging roles of semaphorin4D/CD100 in immunological diseases[J]. Biochem Soc Trans, 2020, 48(6): 2875-2890.
[12] Negishi-Koga T, Shinohara M, Komatsu N, et al.Suppression of bone formation by osteoclastic expression of semaphorin 4D[J]. Nat Med, 2011, 17(11): 1473-1480.
[13] Binmadi NO, Proia P, Zhou H, et al.Rho-mediated activation of PI(4)P5K and lipid second messengers is necessary for promotion of angiogenesis by Semaphorin 4D[J]. Angiogenesis, 2011, 14(3): 309-319.
[14] Basile JR, Barac A, Zhu T, et al.Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B[J]. Cancer Res, 2004, 64(15): 5212-5224.
[15] Wu M, Li J, Gao Q, et al.The role of Sema4D/CD100 as a therapeutic target for tumor microenvironments and for autoimmune, neuroimmune and bone diseases[J]. Expert Opin Ther Targets, 2016, 20(7): 885-901.
[16] Agarwal P, Rao NN.Bisphosphonate-associated osteonecrosis of the jaws[J]. Indian J Dent Res, 2012, 23(1): 107-111.
[17] Caraglia M, Santini D, Marra M, et al.Emerging anti-cancer molecular mechanisms of aminobisphosphonates[J]. Endocr Relat Cancer, 2006, 13(1): 7-26.
[18] Pabst AM, Ziebart T, Ackermann M, et al.Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay[J]. Clin Oral Investig, 2014, 18(3): 1015-1022.
[19] Cornish J, Bava U, Callon KE, et al.Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells[J]. Bone, 2011, 49(4): 710-716.
[20] Rollason V, Laverrière A, MacDonald LC, et al. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ) [J]. Cochrane Database Syst Rev, 2016, 2(2): Cd008455.
[21] Kishimoto H, Noguchi K, Takaoka K.Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ)[J]. Jpn Dent Sci Rev, 2019, 55(1): 95-102.
[22] Özkalayci F, Gülmez Ö, Ugur-Altun B, et al.The role of osteoprotegerin as a cardioprotective versus reactive inflammatory marker: the chicken or the egg paradox[J]. Balkan Med J, 2018, 35(3): 225-232.
[23] 谢冰洁, 冯捷, 韩向龙. 破骨细胞生物学特征的研究与进展[J]. 中国组织工程研究, 2017, 21(11): 1770-1775.
[24] 高鑫, 曾融生. 骨保护素在口腔领域的研究进展[J]. 国际口腔医学杂志, 2019, 46(3): 316-319.
[25] Kim Y, Brodt MD, Tang SY, et al.MicroCT for scanning and analysis of mouse bones[J]. Methods Mol Biol, 2021, 2230: 169-198.
[26] Irie MS, Rabelo GD, Spin-Neto R, et al.Use of micro-computed tomography for bone evaluation in dentistry[J]. Braz Dent J, 2018, 29(3): 227-238.
[27] Zhang Y, Liu B, Ma Y, et al.Sema 4D/CD100-plexin B is a multifunctional counter-receptor[J]. Cell Mol Immunol, 2013, 10(2): 97-98.
[28] Zhu W, Xu R, Du J, et al.Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw[J]. Faseb J, 2019, 33(4): 5208-5219.
[29] Paschalidi P, Gkouveris I, Soundia A, et al.The role of M1 and M2 macrophage polarization in progression of medication-related osteonecrosis of the jaw[J]. Clin Oral Investig, 2021, 25(5): 2845-2857.
[30] Fowler DW, Copier J, Dalgleish AG, et al.Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2+ γδ T cell cytotoxicity in a perforin-dependent manner[J]. Cancer Immunol Immunother, 2017, 66(9): 1205-1215.
[31] Movila A, Mawardi H, Nishimura K, et al.Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw(MRONJ)[J]. Biochem Biophys Res Commun, 2016, 480(1): 42-47.